Publications by authors named "T Westermeier"

Claim this Profile
R
Rivaroxaban: a novel oral anticoagulant for the prevention and treatment of several thrombosis-mediated conditions.
Troy C Sarich, Gary Peters, Scott D Berkowitz, Frank Misselwitz, Christopher C Nessel, Torsten Westermeier

Ann N Y Acad Sci· July 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term improvement of metabolic control by acarbose in type 2 diabetes patients poorly controlled with maximum sulfonylurea therapy.
Werner Bachmann, Dieter Petzinna, Sotirios A Raptis, Thomas Wascher, Torsten Westermeier

Clin Drug Investig· October 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty. Pooled analysis of four studies.
Alexander G G Turpie, Michael Rud Lassen, Bengt I Eriksson, Michael Gent, Scott D Berkowitz, Torsten Westermeier

Thromb Haemost· March 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development and validation of a risk-score model for subjects with impaired glucose tolerance for the assessment of the risk of type 2 diabetes mellitus-The STOP-NIDDM risk-score.
Jaakko Tuomilehto, Jaana Lindström, Martin Hellmich, Walter Lehmacher, Torsten Westermeier

Diabetes Res Clin Pract· February 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Metabolic syndrome and its single traits as risk factors for diabetes in people with impaired glucose tolerance: the STOP-NIDDM trial.
Markolf Hanefeld, Avraham Karasik, Carsta Koehler, Torsten Westermeier, Jean-Louis Chiasson

Diab Vasc Dis Res· January 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis